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Infection with Schistosoma mansoni is a major cause of morbidity and mortality in endemic
areas, and is increasingly diagnosed in migrants and travellers outside transmission areas.
Markers for the assessment of morbidity and impact of control programs in endemic areas
and for the clinical management of patients in the clinical setting are scant, especially for
intestinal involvement. Ultrasonography is well established to evaluate hepatosplenic
pathology; on the contrary, ultrasound evaluation of intestinal schistosomiasis is virtually
unexplored. In this pilot study, we aimed to describe and evaluate the accuracy of unen-
hanced intestinal ultrasound for morbidity due to intestinal S. mansoni infection.
Methodology/Principal findings
We performed a blind case-control study of unenhanced intestinal ultrasound on 107 adults
accessing the outpatient clinic of our Centre for Tropical Diseases between January-July
2018 as part of a screening for tropical diseases in migrants and travellers returning from
endemic areas. Other clinical and laboratory data were obtained routine examination
reports. We could not find any overtly pathological thickness of the gut wall in the sigma,
proximal ascending colon, and terminal ileum, in patients with S. mansoni infection (n = 17),
S. haematobium infection (n = 7), positive anti-Schistosoma serology (n = 31), and unin-
fected individuals (n = 52), with no difference among groups as assessed by ANOVA. No
polyps or other intestinal abnormalities were visualized. There was no significant change in
gut wall thickness one month after treatment with praziquantel in patients with S. mansoni
infection (n = 11).
Conclusions/Significance
Our preliminary results suggest that intestinal ultrasound might not be a sensitive tool for
detecting minor intestinal morbidity due to schistosomiasis. Further studies in a hospital set-
ting comparing colonoscopy and ultrasonography may be envisaged; in endemic areas,







Citation: Tamarozzi F, Buonfrate D, Badona
Monteiro G, Richter J, Gobbi FG, Bisoffi Z (2018)
Ultrasound and intestinal lesions in Schistosoma
mansoni infection: A case-control pilot study
outside endemic areas. PLoS ONE 13(12):
e0209333. https://doi.org/10.1371/journal.
pone.0209333
Editor: Michael H. Hsieh, George Washington
University, UNITED STATES
Received: August 29, 2018
Accepted: December 4, 2018
Published: December 18, 2018
Copyright: © 2018 Tamarozzi et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
further studies are needed to describe and assess the usefulness of intestinal ultrasound in
patients stratified by infection intensity and compared with markers such as calprotectin and
fecal occult blood.
Introduction
Schistosomiasis is a parasitic infection caused by trematodes of the genus Schistosoma,
acquired upon contact with fresh water bodies contaminated with the larval stage of the para-
site. It is estimated that more than 200 million people are infected worldwide by schistosomes
causing either the urinary or the intestinal form of the disease, resulting in over 200 thousand
deaths every year, mostly in Sub-Saharan Africa [1, 2]. Imported schistosomiasis in migrants
and travellers returning from endemic areas has been defined, in receiving countries such as
Italy, as a “hidden epidemic”[3].
S. mansoni, the main causative agent of intestinal and hepatosplenic schistosomiasis, is esti-
mated to infect over 50 million people in endemic areas [4]. Pathology is caused by eggs
released by female parasites residing in the venous plexus draining the large intestine, which
are trapped in the bowel wall and the liver [5]. In recent years, there has been considerable
effort by the international community toward the control of the infection with mass drug
administration of praziquantel [1]. The aim of this strategy is the decrease in morbidity due to
schistosomiasis [6]. However, morbidity markers for assessment of the infection and post-
interventions evaluation are scant [7]. Also at an individual patient’s level, a comprehensive
evaluation of morbidity is difficult due to the variability of schistosomiasis-related clinical
manifestations and lack of specific symptoms.
Morbidity and mortality due to advanced hepatosplenic involvement resulting in liver
fibrosis and portal hypertension are well recognized and described [4, 8]. On the contrary,
morbidity due to involvement of the bowel, which is affected by the inflammatory response to
eggs passing through and entrapped in the mucosa and sub-mucosa, has proven more difficult
to quantify. This is partly due to the variability and lack of specificity of symptoms, which
depend on the extent of inflammation and range from vague abdominal pain to bloody diar-
rhoea. Based on questionnaires data, diarrhoea with or without blood has been estimated to
occur in over 5 million individuals infected with S. mansoni in sub-Saharan Africa, but this
estimate is burdened by high uncertainty [4]. The clinical diagnostic gold standard for intesti-
nal morbidity is colonoscopy, but this has virtually no applicability for disease burden evalua-
tion at population level and is also poorly accepted and repeatable in asymptomatic or pauci-
symptomatic individuals in the clinical setting. Faecal calprotectin and faecal occult blood,
unspecific markers of bowel inflammation, have been recently shown to correlate with parasite
egg excretion and therefore suggested to be of use for monitoring in control programs [9].
Ultrasonography (US) is a particularly appealing tool in the field of infectious diseases
because it is non-invasive, devoid of radiations, repeatable, and can be performed at the bed-
side of the patient with the use of portable machines [10]. Even in case of unspecific findings,
the visualization of the affected organ, complementary to what provided by laboratory tests,
provides useful information on the type and extent of pathology. In S. mansoni infection, US is
a well-established technique to evaluate hepatosplenic pathology [10, 11]. A standardized pro-
tocol for the evaluation and grading of hepatosplenic schistosomiasis using US was issued by
the WHO in 2000 [12] and recently evaluated for usability and usefulness [6]. On the contrary,
reports on the use of US in the evaluation of intestinal schistosomiasis are extremely scant [11,
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13], and there is no US report on the evolution of the lesions, when visualized, after treatment,
either in endemic areas or in case of no risk of reinfection.
There is a need to find low-cost, reliable, and repeatable markers of bowel morbidity that
can aid both the assessment of morbidity and impact of control programs in endemic areas
and the clinical evaluation and follow-up of individual patients in the clinical setting. The pri-
mary objective of this study was to describe and evaluate the accuracy of unenhanced intestinal
US signs for the diagnosis and morbidity assessment of intestinal S. mansoni infection. The
secondary objective was to evaluate the evolution over time of unenhanced intestinal US signs
in patients with S. mansoni infection.
Methods
Ethics statement
The study was approved by the Ethics Committee for Clinical Experimentation of Verona and
Rovigo Provinces, Italy (protocol n. 63537). All adult participants provided written informed
consent; children were excluded from participation.
Study design and participants
This is a case-control, cross-sectional pilot study followed by a longitudinal study of unen-
hanced intestinal US (Fig 1). The study was carried out on a convenience sample of asymptom-
atic/pauci-symptomatic individuals accessing the outpatient clinic of the Centre tor Tropical
Diseases of the IRCCS Sacro Cuore-Don Calabria Hospital of Negrar, Verona, Italy, between
January 1st and July 1st 2018 as part of a screening for tropical diseases in migrants and travel-
lers returning from endemic areas.
Fig 1. Study flowchart and demographic and clinical characteristics of enrolled subjects at first visit. M = males;
F = females; SD = Standard Deviation.
https://doi.org/10.1371/journal.pone.0209333.g001
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Inclusion criteria for the case-control study were: epidemiological risk for S. mansoni infec-
tion, age� 18 years, and no documented evidence of receiving treatment with praziquantel in
the previous 6 months. This period was decided based on the known behaviour on US of blad-
der lesions due to S. haematobium, which resolve completely by 6 months post-treatment (in
the absence of neoplastic transformation) but could be still detectable within this time interval
even in the absence of active infection. Exclusion criteria were advanced pregnancy that could
limit the exploration of the abdomen by US, and known acute (e.g. diverticulitis) or chronic
inflammatory bowel diseases (e.g. Crohn disease or ulcerative rectocolitis). During the routine
screening visit, all individuals underwent, among other exams, a complete blood cells count,
and urine and faecal parasitology. Copromicroscopy after formol-ether concentration was per-
formed for intestinal parasites and PCR for the detection of Schistosoma spp DNA in stool
(modified from [14]). Urine samples were collected between 10 am and 2 pm, concentrated by
filtration, and microscopically evaluated for the presence of S. haematobium eggs and for the
performance of Schistosoma antigen CCA urinary ICT (nal von Minden GmbH, Moer, Ger-
many). Anti-Schistosoma serology was performed by ELISA (Bordier Affinity Products, Criss-
ier, Switzerland) and/or IgM-IgG immunochromatographic (ICT) test (LDBio Diagnostics,
Lyon, France), according to the manufacturer’s instructions. On the same day of the visit, i.e.
before laboratory results were known, individuals confirming their participation to the study
by signing the informed consent form were investigated by abdominal US (all performed by
FT) using a SonoSite M-Turbo (Fijifilm, Washinghton, USA) equipped with convex and linear
probes. For the intestinal US investigation, the sigma, proximal part of ascending colon next to
the ileocecal valve, and terminal ileum were visualized in the area between the iliac vessels and
psoas muscle. The area of maximum gut wall thickness was visually identified in each of these
segments and measured in each segment (in millimetres; primary outcome). Care was taken to
avoid measurement in correspondence to semilunar folds in the colon and during peristaltic
contractions in the ileum. Other abdominal features (presence of abdominal effusion, abnor-
mally dilated bowel loops, enlarged mesenteric lymph nodes, mesenteric hypertrophy)
recorded in the case report form, images and videos. Liver characteristics, including image pat-
tern according to WHO [12], and spleen characteristics on US were also evaluated by US and
recorded. The spleen size was evaluated using both bipolar length in relation to person’s height
[15] and cross-section area [16], measured on a longitudinal scan passing through the splenic
hilum.
Patients with a diagnosis of S. mansoni infection confirmed by microscopy and/or PCR
were re-evaluated by intestinal US one month after completion of therapy with praziquantel
(40 mg/kg/day in 2 divided doses for 3 days). This time point was decided based on experience
with inflammatory lesions of the bladder mucosa in patients with S. haematobium infection,
which either disappear or decrease in size within one month post-therapy in most cases [17–
19]. Inflammatory indexes (Erythrocyte Sedimentation Rate [ESR, normal value <34 mm/H]
and/or C Reactive Protein [CRP, normal value <5 mg/l]) were assessed as part of routine tests,
while signs and symptoms at the time of hospitalization for treatment were obtained from clin-
ical documentation.
Statistical analysis
Individuals were classified as follows: 1) patients with S. mansoni infection confirmed by pres-
ence of S. mansoni eggs in faeces; 2) patients with S. haematobium infection confirmed by
presence of S. haematobium eggs in urine; 3) serological schistosomiasis assessed by at least 1
positive serology test but no detection of eggs in faeces and/or urine; 4) schistosomiasis nega-
tive individuals, with no laboratory sign of infection. Patients with confirmed S. mansoni
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infection were analysed as the cases, while the other groups were considered as controls. Pres-
ence of other intestinal parasitic infections was considered a confounding factor and its distri-
bution among groups evaluated. Unfortunately it was not possible to stratify results according
to infection intensity, which can be a potential effect modifier, as stool examination by Kato-
katz, a poorly sensitive technique not useful for diagnosis at individual patient’s level, is not
part of the routine coproparasitological examination of our hospital. The Shapiro-Wilk test
was used to assess the normal distribution of the data. Continuous variables were described by
mean and standard deviation (SD) and compared by ANOVA in case of independent groups
(case-control study) and by paired T-test in case of paired measures (longitudinal study)
respectively. Categorical variables were described by count and percentage and compared by
Chi-square test. Analyses were performed by MedCalc software (Ostend, Belgium). A p-
value� 0.05 was considered statistically significant.
Results
Participants characteristics
A total of 107 subjects were eligible and they all accepted to take part to the study. The details
of included patients are summarized in Fig 1. No potentially eligible subject by epidemiological
risk had to be excluded due to advanced pregnancy or inflammatory bowel diseases. The coun-
tries of origin of the subjects were: Nigeria (n = 24), Mali (n = 11), Côte d’Ivoire (n = 10), Sene-
gal (n = 10), Angola (n = 8), Republic of Guinea (Guinea Conakry n = 7), the Gambia (n = 7),
Ghana (n = 6), Eritrea (n = 5), Guinea Bissau (n = 3), Burkina Faso (n = 3), Democratic Repub-
lic of the Congo (n = 2), Sierra Leone (n = 2), and Brazil, Cameroon, Italy, Madagascar, Niger,
Somalia, Togo, Uganda (n = 1 each). The Italian patient had probably acquired S. mansoni
infection in Uganda.
One patient had concomitant S. mansoni and S. haematobium infection, and was classified
in the S. mansoni group for the analysis. Among the 17 patients diagnosed with S. mansoni
infection, 16 (94.1%) had positive faecal microscopy, while one (5.88%) was only positive at
stool PCR; of patients with positive faecal microscopy, 13/16 (81.25%) had also positive PCR,
while in 3/16 (18.75%) stool PCR was negative All patients with confirmed S. haematobium
infection were diagnosed by positive microscopy of urine collected around midday, with the
exception of one patient who had negative urine microscopy but presence of parasite eggs in a
biopsy of the urinary bladder mucosa performed in another hospital, because of haematuria.
Among the 31 patients classified as affected by schistosomiasis by serology only, ELISA was
performed in 27 cases, of which 19 (70.37%) were positive, and IgM-IgG ICT was performed
in 22 cases, of which 21 (95.45%) were positive. A discordant result of negative ELISA and pos-
itive ICT was observed in 8 (44.44%) of the 18 cases where both tests were applied, while the
opposite was only observed in one (5.55%) of the 18 cases. Urine CCA antigen test was per-
formed on a total of 66 individuals, with positive results only in 5 patients with S. mansoni
infection, in the patient with both S. haematobium and S. mansoni infections, and in 2 patients
with serological positivity but no parasitological confirmation.
Cross-sectional study
As shown in Fig 2, there was no overtly pathological thickness (>4 mm [20]) of the intestinal
wall in investigated areas in patients with S. mansoni infection. No significant differences were
found with other groups for any of the investigated intestinal segments: sigma (p = 0.811);
ascending colon (p = 0.667); and terminal ileum (p = 0.128). No other pathological abdominal
image could be detected by US in patients with confirmed S. mansoni infection or in the other
groups.
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Concomitant intestinal parasitic infections, assessed by copromicroscopical exam, were
present in 63 (58.88%) subjects, with no significant difference between groups (p = 0.077; Fig
1). These included various combinations of infections with Ascaris lumbricoides, Blastocysts,
Chilomastix mesnili, Endolimax nana, Entamoeba coli, Entamoeba hartmannii, Entamoeba his-
tolytica/dispar complex, Entamoeba polecki, Giardia duodenalis, hookworm, Hymenolepis
nana, Iodamoeba buetschli, Strongyloides stercoralis.
Other characteristics of S. mansoni infected patients and longitudinal study
At diagnosis, no S. mansoni infected patient had US signs of hepatic portal fibrosis, with the
exception of two patients showing a pattern C (“ring echoes and pipe stem” [12]), one of
whom also had a “starry sky” appearance of a normal sized spleen. Mild to moderate spleno-
megaly was observed in 6 patients with S. mansoni infection when the cross-sectional area was
used (mean spleen area in splenomegalic patients = 67.33 cm2, SD 20.28), while also bipolar
size in relation to height was above normal limits in 2 of these patients (15.6 cm and 13 cm in
male patients 175 cm and 165 cm tall, respectively). During hospitalization, no blood nor
mucus in stool was observed in patients infected with S. mansoni; 3 patients had slight pain to
the palpation of the abdomen. Three patients referred “abdominal pain” either presently or in
the past, and 2 reported “occasional red blood in stool in the past”. However, the cultural and
linguistic barriers often present limit the reliability of these data.
ESR was within normal limits in all patients (mean 11 mm/H, SD 6); CRP was normal (1.37
mg/l, SD 0.61) in all patients with the exception of one (8.81 mg/l) who also had splenomegaly
and abdominal pain.
The maximum intestinal wall thickness in each investigated segment was measured one
month after treatment with praziquantel in 11 out of the 17 patients with S. mansoni infection.
There was no significant change in maximum wall thickness of the sigma (p = 0.066), ascend-
ing colon (p = 0.066), and terminal ileum (p = 0.101) one month after treatment (Fig 3)
Discussion
The involvement of the intestine in pathology due to S. mansoni infection, due to the route of
elimination of parasite eggs, is documented by histological and endoscopic findings [21–23]. It
is also reflected in the association between positivity of faecal occult blood and calprotectin
and medium to high egg intensity output in intestinal schistosomiasis [9, 24, 25], and between
schistosomiasis and anaemia [26]. The prompt response to praziquantel of faecal occult blood
Fig 2. Results of the case-control study. Comparison of wall thickness of the investigated intestinal segments in S.
mansoni infected cases (dark grey bars) and control groups (light grey bars). Bars indicate mean values with standard
deviations. P-values refer to ANOVA statistical test.
https://doi.org/10.1371/journal.pone.0209333.g002
Gut ultrasound in Schistosoma mansoni infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0209333 December 18, 2018 6 / 10
and calprotectin most likely indicates rapid mucosal integrity restoration after treatment [9].
Although these laboratory tests could be used as markers of S. mansoni intestinal morbidity,
non-invasive assessment of intestinal pathology, as it could be provided by US, would allow a
more comprehensive assessment of morbidity before and after treatment at both individual
patient level in the clinical setting and in community studies. US reports on intestinal schisto-
somiasis, however, are extremely scant. Dittrich and colleagues [13] performed intestinal US
on 173 individuals in an endemic area of Senegal, reporting intestinal abnormalities in 82% of
patients with documented (Kato-Katz positive) S. mansoni infection and 60% of uninfected
patients, with an apparent positive correlation between infection intensity (eggs per gram of
faeces) and prevalence of abnormalities on US. These included intestinal wall thickening,
pseudo-kidney or cockade-like images, and increased echogenicity of the mucosa and of the
mesenteric structures. None of these abnormalities were detected in our cohort. Many factors
(endemic vs non-endemic area, inclusion vs exclusion of children, different intensity of infec-
tions in the two cohorts, different coproparasitological diagnostic method used, prevalence
and type of concomitant intestinal infections, image resolution of the US machine and of the
probe used–convex low-frequency probe by Dittrich and colleagues vs linear high-frequency
highly accurate probe in our study) could have contributed to the very different results of the
two studies. Also, the reported very high prevalence of abnormal intestinal findings in individ-
uals apparently not infected with S. mansoni supports the hypothesis that the two study popu-
lations were markedly different, and therefore difficult to compare. However, a common
finding was the lack of visualization of polypoid formations, which conversely are detected in
infected patients by colonoscopy [22]. This is consistent with the very low sensitivity of unen-
hanced US for this type of lesions. Sensitivity could be increased by the use of hydrocolonic
sonography [27], however, this technique is time consuming, generally poorly accepted, and
not suitable for large-scale studies.
The absence of visualization of intestinal wall thickening in our cohort of patients eliminat-
ing S. mansoni eggs in faeces was surprising, although this result should be considered prelimi-
nary due to the small sample size. The absence of difference between cases and controls in
intestinal wall thickness, with this being overall within normal limits in all groups, counters
the possible bias deriving from including S. mansoni infected individuals in other control
groups due to low sensitivity of diagnostic methods. It is possible to speculate that only mini-
mal inflammation was expressed in the examined patients. This is supported by the normal
Fig 3. Results of the longitudinal study. Comparison of wall thickness of the investigated intestinal segments in S.
mansoni infected at the time of diagnosis (pre-treatment) and 1 month post-treatment with praziquantel. Bars indicate
mean values with standard deviations. P-values refer to paired T-test statistical test.
https://doi.org/10.1371/journal.pone.0209333.g003
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systemic inflammation markers in almost all patients, as well as by the absence or low preva-
lence of clear signs of infection at diagnosis and reported current or past signs and symptoms.
These, however, are known to have low sensitivity in infected individuals [28] and collection
of an accurate clinical history was often hampered by cultural and linguistic barriers. Unfortu-
nately local markers such as faecal occult blood and calprotectin are not routinely tested in
patients diagnosed with schistosomiasis in our centre, and were therefore not available.
Another limitation of our study is the unknown intensity of infection in terms of eggs per
gram of faeces, as routine copromicroscopical examination in our centre is carried out using
formol-ether concentration and not Kato-Katz. Several epidemiological and intervention stud-
ies found a correlation between S. mansoni infection intensity and morbidity, including portal
fibrosis [29–34]. Considering the overall clinical picture of the patients involved in our cohort,
it is therefore plausible that our cohort of S. mansoni infected patients may have included only
subjects with low intensity infections.
In conclusion, we carried out for the first time a pilot, prospective case-control study of
intestinal unenhanced US for S. mansoni morbidity assessment outside endemic areas, using a
standard protocol and high-resolution US equipment. Our preliminary results suggest that,
although appealing, intestinal US is not likely to be a useful tool in all settings for a more com-
prehensive assessment of morbidity before and after treatment for S. mansoni infection. Fur-
ther studies are needed to describe and assess the usefulness of intestinal US on different
populations, such as in endemic areas and in patients stratified by infection intensity. Ultra-
sound findings may be compared with the results of fecal calprotectin and fecal occult blood
tests [9]. In the hospital setting, studies comparing colonoscopy and ultrasonography could be
envisaged.
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